Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Inflammatory Bowel Disease
•
Gastroenterology
When and how should we use biomarkers (i.e., CRP, stool calprotectin, mAb levels) to guide or optimize medical management of Crohn’s disease or ulcerative colitis?
Related Questions
How would you manage a patient with highly active ankylosing spondylitis, iritis and Crohn’s, controlled with weekly adalimumab with co-morbid IgG4RD and intolerance of azathioprine due to elevated LFTs?
Do you feel comfortable using Jak inhibitors in patients with a strong family history of CAD, but no other risk factors?
How would you approach additional workup and management of a patient with active Crohn’s disease, who has multiple lung and brain nodules, with lung pathology demonstrating necrotizing granulomatous inflammation and brain biopsy with granulomatous inflammation and medium-large vessel vasculitis?
What diet do you recommend for patients with inflammatory bowel disease?
What is your approach to choosing a particular advanced therapy based on patient or disease factors when initiating treatment for moderate-severe IBD?
How do you incorporate intestinal ultrasound in the care of patients with inflammatory bowel disease?
How would active Crohn's on Adalimumab affect the adjuvant management of a T2aN0M0 gallbladder cancer?
Is there a role for use of JAK inhibitors instead of corticosteroids to induce clinical remission in those with severe ulcerative colitis?
What prompts you to seek an alternative PPI versus escalating to PCAB therapy in patients with symptoms and sequelae of GERD who have clinically failed one PPI trial despite appropriate pre-prandial use?
Which colonic polyp or mass-like lesions do you refer to an advanced endoscopist?
